Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06878261 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Study acronym: JOURNEY
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 276 → 284 locations Eligibility criteria expanded, about 16 words · Secondary endpoints: details revised at 8 of 13 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 8 of 13 entries
  2. Trial sites expanded: 268 → 276 locationsv15
  3. 2 versions Re-verified since May 6, 2026, no change to tracked fieldsv13-v14
  4. Study sites: 266 to 268v12
  5. Study sites: 267 to 266v11
Show 9 earlier versionsHide 9 earlier versions
  1. Study sites: 261 to 267v10
  2. Study sites: 260 to 261v9
  3. Eligibility criteria expanded, about 31 words Secondary endpoints: 12 to 13 · Site details revised at 204 of 260 sitesv8 Show 2 more changesShow less
    • Secondary endpoints: 12 to 13
    • Site details revised at 204 of 260 sites

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 257 to 260v7
  5. Study sites: 248 to 257v6
  6. Study sites: 236 to 248v5
  7. Study sites: 218 to 236v4
  8. Study sites: 174 to 218v3
  9. Trial status: Not Yet Recruiting to Recruiting Study sites: 146 to 174 · Start date changed from estimate of Mar 31, 2025 to Mar 25, 2025v2 Show 2 more changesShow less
    • Study sites: 146 to 174
    • Start date changed from estimate of Mar 31, 2025 to Mar 25, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
COPD
1,068 trials monitored
See 31 trials at risk
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Trial Details
NCT Number NCT06878261
Lead Sponsor AstraZeneca
Collaborators: Amgen
Conditions Chronic Obstructive Pulmonary Disease (COPD)
Enrollment 990 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov